Supernus Pharmaceuticals, Inc. (SUPN) — Analysis Summary
Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of $2.76B with year-over-year revenue growth of -0.8%. Net margin stands at 11.2%. The stock trades at a P/E ratio of 37.3.
Key Takeaways
- Revenue changed -0.8% year-over-year
- Net margin of 11.2%
- P/E ratio of 37.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SUPN posted revenue growth of -0.8% and trades at a P/E of 37.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.